Granisetron
Mechanism :
Granisetron is a selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1; 5-HT1A; 5-HT1B/C; 5-HT2; for alpha1-, alpha2-, or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors.
Indication :
Contraindications :
Contraindicated in patients with known hypersensitivity to the drug or any of its components.
Dosing :
Under 2 years:
Safety and efficacy not established.
2-16 years:
0.01 mg/kg intravenous infusion over 5 minutes or half an hour before chemotherapy.
Adverse Effect :
Headache, diarrhea, asthenia, constipation, drowsiness, sedation, somnolence, abdominal pain and dyspepsia.
Interaction :
Phenytoin, Carbamazepine, and Rifampicin: The clearance of granisetron was significantly increased and ondansetron blood concentrations were decreased.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function |
| <10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unknown dialysability. Dose as in normal renal function |
| HD | Unknown dialysability. Dose as in normal renal function. Company recommends timing HD for greater than 2 hours after granisetron dose |
| HDF/High flux | Unknown dialysability. Dose as in normal renal function. Company recommends timing HD for greater than 2 hours after granisetron dose |
| CAV/VVHD | Unknown dialysability. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are needed.